DisclosureWe earn commission on partner links; ranking is set by our published methodology — not advertisers.
Weight loss is the core on-label GLP-1 indication. Wegovy (semaglutide) and Zepbound (tirzepatide) are FDA-approved for chronic weight management at BMI ≥ 30, or ≥ 27 with a weight-related comorbidity.
STEP 1 (NEJM 2021, n=1961) showed semaglutide 2.4 mg produced 14.9% mean body-weight loss at week 68 vs 2.4% on placebo, with 86.4% of patients losing ≥ 5%. SURMOUNT-1 (NEJM 2022, n=2539) showed tirzepatide 15 mg produced 20.9% mean loss at week 72 on the treatment-regimen (intention-to-treat) estimand — up to 22.5% on the efficacy estimand — vs 3.1% on placebo. SURMOUNT-5, a head-to-head trial, found tirzepatide superior to semaglutide for weight loss. Liraglutide 3.0 mg (SCALE) is the older, lower-efficacy option. An oral semaglutide tablet (Wegovy) became the first FDA-approved oral GLP-1 for weight management in January 2026.
On-label prescribing requires BMI ≥ 30, or BMI ≥ 27 with at least one weight-related comorbidity (hypertension, dyslipidemia, type 2 diabetes, or obstructive sleep apnea). Zepbound and Wegovy are the first-line injectables; Saxenda (daily) is largely superseded. Mounjaro and Ozempic are the diabetes-indicated molecules and are increasingly denied for off-label weight-loss use in 2026 — use the weight-loss-indicated brand to match the FDA label.
Commercial PA approval hinges on documenting BMI plus comorbidity against the FDA label. Plans that exclude weight-loss drugs entirely will not approve any pathway on BMI alone; an adjacent on-label indication (OSA-with-obesity for Zepbound, established ASCVD for Wegovy) is often the only route. NovoCare and LillyDirect cash-pay channels work regardless of coverage.
Boxed warning for risk of thyroid C-cell tumors; contraindicated in personal/family history of medullary thyroid carcinoma or MEN 2. Most common adverse events are GI (nausea, vomiting, diarrhea). Roughly 25-40% of weight lost can be lean body mass without resistance training and adequate protein (1.2-1.6 g/kg). Weight regain is common after discontinuation.
This is the indication with the strongest, most replicated evidence in the category. For BMI ≥ 30, or ≥ 27 with a comorbidity, tirzepatide (Zepbound) has the highest published efficacy; semaglutide (Wegovy) has the deepest cardiovascular and long-term safety dataset. Plan for chronic, not time-limited, therapy and prioritize protein and resistance training to protect lean mass.
Yes. Switching from Ozempic (semaglutide) to Mounjaro (tirzepatide) is common and clinically supported for type 2 diabetes patients seeking better A1C reduction.
Yes. Switching from Wegovy (semaglutide) to Zepbound (tirzepatide) is supported when Wegovy intolerance, plateau, or coverage loss occurs. Restart titration at Zepbound 2.5mg.
On raw weight loss, yes — Zepbound delivers ~22% body weight loss vs Wegovy ~15% in clinical trials. On cardiovascular outcomes evidence, Wegovy is ahead.
Most GI side effects (nausea, constipation, sulfur burps) resolve within 4-8 weeks as your body adjusts. Side effects flare again with each dose escalation.
Side effect profiles are similar. Zepbound users report slightly more fatigue at higher doses (10mg+). Wegovy users report more sulfur burps. Discontinuation rates ~comparable.
Yes, in moderation. Alcohol on Wegovy is not contraindicated, but most patients report dramatically reduced tolerance — 1-2 drinks may feel like 3-4.
Editorial summary, not medical advice. Off-label and emerging uses should be discussed with a qualified clinician. Trial outcomes do not predict individual results.